Generium Next

History

2025: Opening a new drug plant in Moscow for ₽8,5 billion

Moscow Mayor Sergei Sobyanin opened the production complex of Generium-Next LLC from the Pharmstandard group of companies at the Alabushevo site of the Technopolice Moscow special economic zone. Investments in the implementation of the project amounted to more than ₽8,5 billion. Construction began in 2022 and was completed in October this year. A modern pharmaceutical enterprise with an area of ​ ​ 28.1 thousand square meters was erected on a land plot of 2.2 hectares. The plant will employ 250 people. This was announced by the portal of the mayor of Moscow on October 7, 2025.

The opening took place on the Day of Moscow Industry. Sergei Sobyanin congratulated representatives of the Moscow industry on the holiday. According to him, in recent years, Moscow's manufacturing industries have increased their products 2.8 times. Every year, from 100 to 150 new high-tech enterprises are registered in the capital. The new industrialization of Moscow is taking place at an active pace. Moscow is again turning into one of the leaders in the field of industry. The technological independence of the country requires the development of its own industries.

𝓲

Фото: Maxim Mishin. Press Service of the Mayor and the Government of Moscow

The Mayor of Moscow called pharmaceuticals one of the leaders in production with dynamic development. The city has more than 300 enterprises - manufacturers of medicines and medical devices. About 30 thousand people work at pharmaceutical factories. The volume of production of the capital industry has grown 2.8 times over the past 15 years. The largest cluster of metropolitan pharmaceuticals operates on the basis of the SEZ "Technopolice Moscow." There are already eight production facilities at the site. The Generium-Next plant became the ninth enterprise in the cluster.

Sergei Sobyanin noted at the opening that the new plant for the production of vital drugs will provide not only Muscovites. Citizens of the whole country will have access to the products of the enterprise. Supplies of drugs for export will open foreign markets. A significant part of the equipment was created by domestic manufacturers. Import substitution in pharmaceuticals reduces dependence on foreign technology suppliers.^[1]

2024: Construction of the plant for billions of rubles

On May 7, 2024, it became known about the completion of the construction of the pharmaceutical plant of the Generium-Next company in Moscow. This enterprise will produce drugs for the treatment of bronchial asthma, cardiovascular, rare and hereditary diseases.

The production complex of Generium-Next is located at the Alabushevo site of the Technopolice Moscow SEZ in the Zelenograd district of Silino. The company plans to produce about 150 thousand units of products per year. It is expected that it will be produced mainly from domestic raw materials, the localization level will be 90%.

𝓲

Фото: Unsplash

Earlier, the expert council of the FRP approved the company Generium-Next, owned by Generium JSC, a loan in the amount of 2 billion rubles under the Priority Projects program.

The total investment in the creation of the enterprise, as the Deputy Mayor of Moscow for Economic Policy and Property and Land Relations Vladimir Efimov said earlier, is almost 5 billion rubles.

By May 2024, Generium-Next rents a room with an area of ​ ​ about 500 square meters at the Alabushevo site. The company also launched a workshop for secondary packaging and production of drugs for the treatment of complications of bronchial asthma and rare, so-called orphan diseases, including Gaucher disease and cystic fibrosis.

Generium-Next has the status of a resident of the special economic zone of Moscow, which allows it to receive significant benefits. Such enterprises are exempted from paying property, transport and land taxes for 10 years. The income tax rate for them is just two per cent. There is also a free customs zone regime and benefits for renting land allocated for the construction of the enterprise, and upon completion, it is possible to redeem the leased plot for one percent of the cadastral value.^[2]

Notes